newsfilter
← Latest News
GlobeNewswire·

Mereo BioPharma Provides Corporate Update

Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing to determine potential path forward for the program Cash balance of approximately $41 million as